Studies on the synthesis of derivatives of marine-derived bostrycin and their structure-activity relationship against tumor cells

Article abstract of DOI:10.3390/md10040932

A series of new derivatives (5-29) of marine-derived bostrycin (1) were synthesized. The in vitro cytotoxic activities of all compounds were evaluated against MCF-7, MDA-MB-435, A549, HepG2, HCT-116 and MCF-10A cells using the MTT method. The compounds 7,

Full text of DOI:10.3390/md10040932

Mar. Drugs 2012, 10, 932-952; doi:10.3390/md10040932
OPEN ACCESS
Marine Drugs
ISSN 1660-3397
www.mdpi.com/journal/marinedrugs
Article
Studies on the Synthesis of Derivatives of Marine-Derived
Bostrycin and Their Structure-Activity Relationship against
Tumor Cells
Hong Chen 1,2, Lili Zhong 1,2, Yuhua Long 3, Jia Li 1,2, Jueheng Wu 2,4,5, Lan Liu 1,2
,
Shengping Chen 2,4,5, Yongcheng Lin 1,2, Mengfeng Li 2,4,5, Xun Zhu 2,4,5,* and Zhigang She 1,2,
*
1
School of Chemistry and Chemical Engineering, Sun Yat-sen University, 135 Xingang West Road,
Guangzhou 510275, China; E-Mails: chenwexpo@sina.com (H.C.); zhonglili42@yahoo.com.cn (L.Z.);
nuekagami@163.com (J.L.); cesllan@mail.sysu.edu.cn (L.L.); ceslyc@mail.sysu.edu.cn (Y.L.)
Guangdong Province Key Laboratory of Functional Molecules in Oceanic Microorganism,
Bureau of Education, Sun Yat-sen University, 74 Zhongshan Road II, Guangzhou 510080, China;
E-Mails: wujh@mail.sysu.edu.cn (J.W.); chenshp@mail.sysu.edu.cn (S.C.);
limf@mail.sysu.edu.cn (M.L.)
2
3
4
5
School of Chemistry and Environment, South China Normal University, 348 West Outer Ring Road,
Guangzhou 510006, China; E-Mail: longyh@scnu.edu.cn
Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University,
74 Zhongshan Road II, Guangzhou 510080, China
Key Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University,
74 Zhongshan Road II, Guangzhou 510080, China
* Authors to whom correspondence should be addressed; E-Mails: zhuxun8@mail.sysu.edu.cn (X.Z.);
cesshzhg@mail.sysu.edu.cn (Z.S.); Tel.: +86-20-8733-2748 (X.Z.); +86-20-8411-3356 (Z.S.);
Fax: +86-20-8733-0209 (X.Z.); +86-20-8411-3356 (Z.S.).
Received: 23 February 2012; in revised form: 10 April 2012 / Accepted: 12 April 2012 /
Published: 24 April 2012
Abstract: A series of new derivatives (5–29) of marine-derived bostrycin (1) were
synthesized. The in vitro cytotoxic activities of all compounds were evaluated against
MCF-7, MDA-MB-435, A549, HepG2, HCT-116 and MCF-10A cells using the MTT
method. The compounds 7, 8, 22, 23, 25, 28 and 29 of the total showed comparable activity
to epirubicin, the positive control, against the tested cancer cell lines. However, these
compounds also exhibited cytotoxicity towards MCF-10A cells. The structure-activity
relationship (SAR) of bostrycin derivatives was also discussed based on the obtained
experimental data.

Mar. Drugs 2012, 10
Keywords: bostrycin; synthesis; antitumor; derivatives; structure-activity relationship
933
1. Introduction
A variety of tetrahydroanthraquinone derivatives isolated from fungi [1–6] and plants [7] display
various biological properties including antibacterial [3,6], antiprotozoal [8], phytotoxic [9] and
cytotoxic activities [7,10]. Previous studies have shown that tetrahydroanthraquinone derivatives can
inhibit the growth of cultured cells of Nicotiana rustica, and act as a potent stimulator of NADH
oxidation in mitochondria and electron acceptors in an enzyme preparation of diaphorase [11].
Bostrycin (1, Figure 1), a natural tetrahydroanthraquinone compound, was isolated from the mangrove
endophytic fungus No. 1403 collected from the South China Sea, as well as three bostrycin analogues
(2–4, Figure 1) [12–14]. The originally proposed structure of bostrycin was identified by interpretation
1
of spectral date (IR, UV, MS, H NMR, 13C NMR) [15–17], and then revised by Kelly and his
co-workers [18] on the basis of the total synthesis of (+/−)-bostrycin and an X-ray crystal structure of
the O-isopropylidene derivative. Subsequently, Larsen’s group [19] revised the absolute configuration
of (−)-bostrycin through an elegant asymmetric synthesis of (+)-bostrycin. Our recent studies have
shown that bostrycin has broad-spectrum antitumor activity [13,14,20,21]. Bostrycin can induce
apoptosis of breast cancer cells through Akt/FOXO pathway, revealing it is a potent apoptosis
inducer [20]. Bostrycin also showed lethal cytotoxicity to yeast cells by inducing apoptosis via an
Aif1p-dependent, mitochondria-mediated apoptotic pathway [22]. Chen et al. [23] reported that
bostrycin can inhibit proliferation of human lung carcinoma A549 cells via downregulation of the
P13K/Akt. The pharmacological and toxicological profiles of bostrycin, as well as its in vivo antitumor
efficacy, provided us with reasonable optimism that bostrycin could become a promising Akt inhibitor
and anticancer drug candidate [20]. However, there have been few studies on the structural
modification and structure-activity relationship (SAR) of bostrycin. Therefore, our research interest
was focused on the modification of bostrycin and its SAR study with the intention of discovering novel
antitumor agents from bostrycin derivatives. In this work, a series of bostrycin derivatives (5–29,
Schemes 1–3) were synthesized with variation at positions 2, 3, 6 and 7 of the tetrahydroanthraquinone
core. All these natural and synthesized compounds were evaluated for their cytotoxic activities against
five human cancer cell lines MCF-7, MDA-MB-435, A549, HepG2 and HCT-116, and one
immortalized human breast epithelial cell line MCF-10A. The SAR was further discussed on the basis
of the obtained experimental data. As we expected, some of the modified compounds exhibited strong
anticancer activities against the tested cancer cells, with superior potency over the parent bostrycin.

Mar. Drugs 2012, 10
934
Figure 1. Structures of bostrycin (1), deoxybostrycin (2), nigrosporin B (3) and
austrocortinin (4).
O
5
OH
O
OH
4
10
O
O
3
4a
9a
10a
6
OH
OH
OH
OH
7
2
8a
9
1
8
O
OH OH
O
OH
bostrycin (1)
deoxybostrycin (2)
O
OH
O
O
O
OH
OH
O
OH
OH
O
nigrosporin B (3)
austrocortinin (4)
Scheme 1. Synthesis of 2,3-ketal/substituted bostrycin derivatives 5–8.
O
OH
O
O
2,2-dimethoxypropane
TsOH, THF, r.t.
3'
O
O
1'
2'
O
O
OH OH
5
OH
5'
3'
3-methyl-2-butenal
TsOH, THF, r.t.
O
O
1'
O
O
OH
4'
O
O
OH OH
6
O
OH
OH
OH
O
O
OH OH
Polyoxymethylene
TsOH, THF, r.t.
O
O
bostrycin
2'
O
O
OH OCH2OH
1'
7
OH
O
O
Triphosgene, pyridine
O
CH Cl , -10
°C
2
2
O
OH OH
8

Mar. Drugs 2012, 10
935
Scheme 2. Synthesis of 6-aminosubstituted bostrycin derivatives 9–22.
O
OH
O
OH
O
R
Amines
OH
OH
OH
OH
MeOH, r.t.
O
OH OH
O
OH OH
bostrycin
9-22
1'
O
NH
NH
NH
NH
NH
9 R =
10 R =
11 R =
12 R =
13 R =
NH
NH
NH
OH
NH H2C
F
14 R =
15 R =
16 R =
17 R =
18 R =
19 R =
20 R =
21 R =
22 R =
1"
3'
3'
1'
N
1'
4'
4'
6'
6'
N
O
3"
3'
3'
1'
1'
1"
NH H2C
NH H2C
4'
4"
N
4'
6'
6"
6'
OH
O
Scheme 3. Synthesis of 6,7-thiosubstituted bostrycin derivatives 23–29.
2. Results and Discussion
2.1. Chemistry
Bostrycin (1) and its analogues (2–4, Figure 1) were isolated from the mangrove endophytic fungus
No. 1403 collected from the South China Sea [12–14]. To explore the effects of hydroxyl groups at C-2
and C-3 positions in bostrycin on antitumor activity, 2,3-ketal/substituted derivatives 5–8 were
synthesized (Scheme 1). Bostrycin was reacted with 2,2-dimethoxypropane, 3-methyl-2-butenal and

Mar. Drugs 2012, 10
936
polyoxymethylene in the presence of 1 equiv of p-toluenesulfonic acid (TsOH) at room temperature,
2,3-ketal derivatives 5, 6 and 7 were obtained respectively. Moreover, treatment of Bostrycin with
triphosgene in the presence of pyridine at −10 °C gave compound 8.
The nucleophilic substitution of 2,3-dichloro-1,4-naphthoquinone by various nucleophiles was
employed as the key reaction [24–27] to afford the structurally diverse derivatives with variation on
the C-6 and C-7 positions of bostrycin. We studied the reaction of bostrycin with various amines
(Scheme 2) and thiols/dithiols (Scheme 3). When bostrycin was treated with various types of amines at
room temperature or 50 °C using methanol as solvent, a series of alkyl/arylamino derivatives 9–22
were obtained (Scheme 2). In addition, the preparation of compounds 15 and 16 required a longer
reaction time and higher temperature presumably due to the low reactivity of the aryl amines used.
This reaction involved a typical nucleophilic displacement of the methoxy group in bostrycin (1) with
various amines as nucleophiles. The possible mechanism is depicted as in Figure 2. When bostrycin
reacted with various thiols and dithiols at 0–5 °C in the presence of triethylamine, a series of alkylthio
disubstituted derivatives 23–29 (at C-6 and C-7) were obtained (Scheme 3). We deduced the dithio
substituted compounds might be obtained through two steps. Firstly, nucleophilic addition of an
alkylthio anion to C-6 followed by elimination of the methoxy group to give a monothio substituted
bostrycin intermediate. However, the second addition of another mole of alkylthio anion to C-7 can be
smoothly carried out due to its strong nucleophilicity, and then tautomerization between the ketone and
enol configuration takes place. Subsequently, the diphenol structure was oxidized to the target quinone
structure (23–29) by the remaining large amount of starting material bostrycin and/or oxygen from the
air. The detailed mechanism is proposed as in Figure 3. The structures of all the compounds were
13
established on the basis of their nuclear magnetic resonance spectra (1H NMR, C NMR) and mass
spectra (ESI, EI).
Figure 2. Nucleophilic substitution of bostrycin and amines.
O
O
OH
R
O
OH
O
OH
R NH2
NH2
O
R
O
NH
O
addition
OH
OH
OH
OH
OH
OH
OH OH
O
OH OH
OH OH OH
O
H
OH
O
OH
H
N
N
- CH3O
- H
OH
OH
OH
OH
OH OH OH
O
OH OH
9-22

Mar. Drugs 2012, 10
937
Figure 3. Nucleophilic substitution of bostrycin and thiols.
O
O
OH
O
OH
O
OH
RS
R
S
R S
O
O
O
addition
+ H
OH
OH
OH
OH
OH
OH
OH OH
O
O
OH OH
O
OH OH OH
OH
OH
RS
RS
RS
- H
- CH3O
OH
OH
OH
OH
addition
OH OH OH
O
OH OH
OH OH
OH OH
RS
RS
RS
[O]a
tautomerization
OH
OH
OH
OH
H
RS
oxidation
O
OH OH
OH
OH OH OH
O
RS
RS
OH
OH
O
OH OH
23-29
O
OH
O
a: [O] is
and/or the oxygen of air
OH
OH
O
OH OH
2.2. Biological Activity
All compounds were evaluated for their in vitro cytotoxic activity against five human cancer cell
lines including human breast MCF-7, human breast MDA-MB-435, human lung A549, human liver
HepG2 and human colon HCT-116, and compared with their effects on the immortalized human breast
epithelial cell line MCF-10A by MTT assay [20,28] using epirubicin (an anticancer drug used widely
in the clinic [29–31]) as positive control. The results are summarized in Table 1 and discussed below.
Table 1. Cytotoxicity of compounds 1–29 against MCF-7, MDA-MB-435, A549, HepG2,
HCT-116 and MCF-10A cells (IC50, μM) a.
Compound/
MCF-7 b
MDA-MB-435 b
A549 b
HepG2 b
HCT-116 b
MCF-10A b
Cell Line
1
2
3
2.18 ± 0.14
2.69 ± 0.31
6.19 ± 0.60
2.82 ± 0.17
3.19 ± 0.92
2.91 ± 0.18
2.63 ± 0.33
4.49 ± 0.13
4.72 ± 0.17
7.71 ± 0.72
9.99 ± 0.55
31.01 ± 0.71
4.78 ± 0.03
5.69 ± 0.25
4.70 ± 0.39
14.08 ± 0.58
13.83 ± 0.76
28.63 ± 0.91

Mar. Drugs 2012, 10
938
Table 1. Cont.
4
>50
41.59 ± 2.63
5.96 ± 0.21
11.67 ± 1.18
4.25 ± 0.57
1.26 ± 0.12
>50
>50
>50
>50
>50
5
6.87 ± 0.33
7.99 ± 0.09
2.52 ± 0.26
1.59 ± 0.16
3.58 ± 0.65
13.97 ± 0.98
1.08 ± 0.21
4.87 ± 0.23
35.55 ± 1.40
>50
4.25 ± 0.16
5.50 ± 0.24
0.78 ± 0.04
0.52 ± 0.02
36.95 ± 1.97
22.34 ± 2.89
4.58 ± 0.50
3.32 ± 0.58
11.03 ± 1.35
7.83 ± 0.32
3.06 ± 0.10
2.92 ± 0.06
34.24 ± 1.27
26.38 ± 0.89
36.46 ± 0.53
4.06 ± 0.65
35.93 ± 1.13
>50
18.11±1.30
34.15 ± 0.85
4.79 ± 0.52
21.72 ± 1.45
>50
6
7
8
9
10
31.07 ± 1.94 22.35 ± 1.16
21.50 ± 1.43 18.00 ± 0.60
25.14 ± 0.74 35.68 ± 1.29
>50
>50
11
>50
>50
Nt c
12
4.25 ± 0.75
>50
3.74 ± 0.67
>50
12.91 ± 0.96
32.16 ± 2.43
>50
13
>50
14
>50
>50
>50
15
3.72 ± 0.27
39.44 ± 0.68
28.66 ± 2.37
9.17 ± 0.28
7.94 ± 0.26
3.14 ± 0.31
4.62 ± 0.44
4.81 ± 0.40
0.71 ± 0.01
2.45 ± 0.48
2.60 ± 0.45
14.42 ± 0.42
6.01 ± 0.39
0.57 ± 0.04
3.18 ± 0.22
0.96 ± 0.08
10.32 ± 0.45
36.41 ± 2.08
40.37 ± 1.49
25.56 ± 1.71
7.86 ± 1.20
4.04 ± 0.35
6.38 ± 0.47
0.95 ± 0.13
0.76 ± 0.06
7.05 ± 0.56
10.64 ± 1.11
13.33 ± 0.20
3.19 ± 0.15
0.63 ± 0.45
0.55 ± 0.11
0.56 ± 0.06
4.87 ± 0.43
>50
4.84 ± 0.25
43.27 ± 1.56
20.63 ± 0.37
13.63 ± 1.85
4.92 ± 0.38
2.81 ± 0.31
3.25 ± 0.67
0.75 ± 0.05
0.95 ± 0.06
3.25 ± 0.54
0.74 ± 0.10
11.95 ± 1.53
3.08 ± 0.35
0.68 ± 0.08
0.73 ± 0.02
0.48 ± 0.03
41.60 ± 0.51
Nt c
16
41.44 ± 2.86 30.31 ± 1.63
17
21.30 ± 2.02
15.18 ± 0.42
6.25 ± 0.43
3.16 ± 0.23
3.06 ± 0.46
0.76 ± 0.03
4.07 ± 0.51
4.06 ± 0.42
0.71 ± 0.01
>50
19.79 ± 0.63
27.69 ± 0.93
7.50 ± 0.69
Nt c
Nt c
Nt c
18
>50
19
>50
20
1.99 ± 0.17
6.09 ± 1.14
6.61 ± 1.12
6.90 ± 0.26
4.03 ± 0.13
3.33 ± 0.66
21
22
23
14.79 ± 0.96
30.64 ± 2.54
34.96 ± 1.94
Nt c
24
25
26
26.12 ± 3.15 22.66 ± 1.95
27
7.31 ± 0.58
0.37 ± 0.04
4.06 ± 0.35
0.61 ± 0.05
3.18 ± 0.75
0.82 ± 0.01
2.55 ± 0.55
0.96 ± 0.02
Nt c
28
0.81 ± 0.11
Nt c
29
epirubicin d
0.48 ± 0.08
a IC50 values are taken as means ± standard deviation from three independent experiments; b MCF-7, human breast cancer
cell line; MDA-MB-435, human breast cancer cell line; A549, human lung cancer cell line; HepG2, human liver cancer
cell line; HCT-116, human colon cancer cell line; MCF-10A, the immortalized human breast epithelial cell line;
c Nt = not tested; d Used as a positive control.
Bostrycin analogues 2 and 3 exhibited comparable cytotoxic activity to bostrycin against all tested
cancer cell lines, except for compound 3 for HepG2 cells, while compound 4 lost potency
(IC50 > 50 μM). The activity profiles suggested that the hydroxyl groups at C-1 and/or C-10 in
bostrycin were not essential for the cytotoxic activity whereas the tetrahydroaromatic ring with the
polyhydroxyl groups was the key pharmacophore of bostrycin.
These bostrycin derivatives were tested on inhibitory activity against the growth of several tumor
cell lines along with one immortalized human breast epithelial cell line. As shown in Table 1, some
modified compounds exhibited much better activity than bostrycin, and even displayed comparable
activity to epirubicin against the cancer cells tested. However, the majority of compounds were also
highly cytotoxic to the immortalized human breast epithelial cells. For example, the activities of
compounds 7 (IC50 = 0.78 μM) and 8 (IC50 = 0.52 μM) against A549 cells have comparable activity to
those of epirubicin (IC50 = 0.61 μM). A similar potency profile was observed with compounds 22

Mar. Drugs 2012, 10
939
(against MDA-MB-435, A549 and HCT-116 cells), 23 (against MCF-7, MDA-MB-435 and HCT-116
cells), 25 (against A549 and HCT-116 cells) and 29 (against MDA-MB-435 and HCT-116 cells).
Significantly, compound 28 showed broad-spectrum antitumor activity, with equal potency to
epirubicin against MCF-7, MDA-MB-435, A549, HepG2 and HCT-116 cells lines with IC50 values of
0.57, 0.63, 0.37, 0.82 and 0.68 μM, which were 3.8-, 4.5-, 7.1-, 9.4- and 7.0-fold more active than
bostrycin (with IC50 value of 2.18, 2.82, 2.63, 7.71 and 4.78 μM), respectively. However, these
compounds also exerted marked cytotoxic effect on immortalized human breast epithelial cells.
Moreover, compounds 7 and 8 exhibited excellent selective activity for A549 cells over other cancer
cells, and the cytotoxic activity of compounds 9 and 11 against MCF-7 cell line was much stronger
than for other kinds of cancer cell lines. Compound 28 (IC50 = 0.57 μM) possessed the most potent
activity against HepG2 cells. The SAR analysis revealed that: (1) 2,3-ketal derivatives 5 and 6 showed
a slight decrease in antiproliferative activity compared to bostrycin. However, compound 8 displayed
stronger activity, which indicated that the protection of C-2 and C-3 with a dioxylcarbonyl group was
favorable for activity; (2) Compound 7 with a hydroxymethyl group at C-1 position and a methylene
group at C-2 and C-3 positions, showed comparable activity to epirubicin for A549 cells;
(3) Secondary heterocyclic amine-substituted derivatives (20–22) possessed more potency than
primary amine-substituted derivatives (9–11 and 13–19) against all cancer cells except for MCF-7
cells. The results suggested that derivatives bearing tertiary amino groups have better activity than
derivatives bearing secondary amino groups; (4) Although compounds 9 and 11 displayed significantly
decreased potency compared to that of bostrycin against five human cancer cells except for MCF-7
cells, they had improved selectivity for MCF-7 cells over other cancer cells; (5) Compared to
alkylamino derivatives 9–11, longer alkylamino substituents seems beneficial for anticancer activity,
as exemplified by compound 12 with significantly improved activity against MDA-MB-435, A549 and
HCT-116 cells; (6) Phenylamino-substituted derivative 15 exhibited better antiproliferative activity
than all other primary amine-substituted derivatives against A549 and HCT-116 cells, except for
compound 12; (7) Compared to derivatives 20, 21, 4-phenylpiperidine-substituted derivative 22
exhibited comparable activity to epirubicin against MDA-MB-435, A549 and HCT-116 cells, which
indicated that a larger group substituted at the 6-piperidine position may be helpful for activity;
(8) Disubstituted thiol derivatives 23–25 and 27 showed strong cytotoxic activity against five human
cancer cell lines with IC50 values of 0.71–10.64 μM; (9) The length of the carbon chain of alkylthio
substituents also affected the antiproliferative activity of the compounds against different cancer cells.
For example, for compounds 23–25, the activity to inhibit the growth of MCF-7 and MDA-MB-435
cells was decreased as the length of the carbon chain of alkylthio substituents was increased. However,
for A549 and HepG2 cells, the order of activity was reversed; (10) Dithiol-substituted derivatives 28,
29 displayed potent cytotoxic activity against five human cancer cell lines, especially, compound 28
which generally exhibited comparable activity to epirubicin against five human cancer cell lines.

Mar. Drugs 2012, 10
940
3. Experimental Section
3.1. Chemistry
Reagents and solvents were commercially available. Solvents were dried and purified using
standard procedures prior to use. Melting points were measured on an X-4 micromelting point
apparatus and were uncorrected. IR spectra were measured on a Bruker Vector 22 spectrophotometer
using KBr pellets. NMR spectra were determined on a Varian Inova-500 NB spectrometer or Bruker
AV-400 NB spectrometer in CDCl3 or DMSO-d6 using TMS as internal standard, and coupling
constants (J) are in Hz. EI mass spectra were recorded on a DSQ mass spectrometer and ESI mass
spectra were obtained on a LCQ DECA XP LC-MS mass spectrometer. Flash column chromatography
was performed with silica gel (Qing dao Ocean Chemical Factory, 200–300 mesh) eluted with
petroleum ether–dichloromethane or dichloromethane–methanol, and C18 reversed phase silica gel
(Welch Material, Inc., 45 μm) eluted with methanol–water.
3.2. Preparation of Bostrycin (1), Deoxybostrycin (2), Nigrosporin B (3) and Austrocortinin (4)
Bostrycin (1) and its analogues (2–4) were isolated from the secondary metabolites of the mangrove
endophytic fungus Nigrospora sp. No. 1403 collected from the South China Sea according to literature
procedures [12–14].
Bostrycin (1). Red solid (MeOH); mp: 252–254 °C; [α]2D5 −272 (c 2.2 × 10−4, MeOH); IR (KBr):
νmax = 3532, 3512, 3480, 3367, 3031, 2991, 2934, 2893, 2857, 1595, 1478, 1460, 1441 cm−1; 1H NMR
(400 MHz, DMSO-d6): δ 13.39 (s, 1H, 9-OH), 12.63 (s, 1H, 10-OH), 6.48 (s, 1H, 7-H), 5.23
(d, J = 4.9 Hz, 1H, 1-OH), 4.93 (d, J = 4.8 Hz, 1H, 2-OH), 4.75 (t, J = 4.9 Hz, 1H, 1-H), 4.48 (s, 1H,
3-OH), 3.92 (s, 3H, 6-OMe), 3.53 (t, J = 4.8 Hz, 1H, 2-H), 2.74 (d, J = 18.2 Hz, 1H, 4-Hb), 2.67
13
(d, J = 18.2 Hz, 1H, 4-Ha), 1.23 (s, 3H, 3-CH3); C NMR (125 MHz, DMSO-d6): δ 184.29 (C-8),
177.49 (C-5), 160.45 (C-9), 160.22 (C-6), 160.07 (C-10), 139.44 (C-9a), 136.80 (C-4a), 109.85 and
109.51 (C-7 and C-10a), 107.49 (C-8a), 76.40 (C-2), 69.33 (C-3), 68.30 (C-1), 56.97 (6-OMe), 34.89
(C-4), 25.67 (3-CH3); EIMS m/z 336 [M]+ (23), 318 (17), 303 (9), 289 (19), 271 (12), 263 (100),
247 (11), 234 (35), 216 (16).
Deoxybostrycin (2). Red solid (MeOH); mp: 224–225 °C; [α]2D5 +90.9 (c 1.1 × 10−4, MeOH);
1H NMR (300 MHz, DMSO-d6): δ 13.18 (s, 1H, 9-OH), 12.62 (s, 1H, 10-OH), 6.42 (s, 1H, 7-H), 4.82
(d, J = 5.1 Hz, 1H, 2-OH), 4.48 (s, 1H, 3-OH), 3.88 (s, 3H, 6-OMe), 3.61 (dt, J = 7.3, 5.1 Hz, 1H, 2-H),
2.82 (dd, J = 18.3, 5.1 Hz, 1H, 1-Hb), 2.77 (d, J = 18.1 Hz, 1H, 4-Hb), 2.64 (dd, J = 18.3, 7.3 Hz, 1H,
1-Ha), 2.56 (d, J = 18.1 Hz, 1H, 4-Ha), 1.18 (s, 3H, 3-CH3); 13C NMR (125 MHz, DMSO-d6): δ 183.39
(C-8), 176.35 (C-5), 161.31 (C-10), 160.38 (C-6), 159.67 (C-9), 138.88 (C-9a), 136.33 (C-4a), 109.47
(C-7), 108.97 (C-10a), 106.85 (C-8a), 70.12 (C-2), 68.81 (C-3), 56.95 (6-OMe), 35.72 (C-4),
29.91 (C-1), 25.39 (3-CH3); EIMS m/z 320 [M]+ (100), 302 (41), 287 (30), 259 (61), 247 (96),
234 (20), 219 (45), 205 (10).
Nigrosporin B (3). Yellow solid (MeOH); mp: >300 °C; [α]2D5 +131.4 (c 1.75 × 10−4, MeOH);
1H NMR (400 MHz, DMSO-d6): δ 12.67 (s, 1H, 9-OH), 7.26 (s, 1H, 10-H), 6.29 (s, 1H, 7-H),
4.76 (d, J = 3.6 Hz, 1H, 2-OH), 4.39 (s, 1H, 3-OH), 3.88 (s, 3H, 6-OMe), 3.66 (m, 1H, 2-H), 2.93

Mar. Drugs 2012, 10
941
(d, J = 17.5 Hz, 1H, 4-Hb), 2.85 (dd, J = 18.4, 4.9 Hz, 1H, 1-Hb), 2.77 (d, J = 17.5 Hz, 1H, 4-Ha), 2.69
(dd, J = 18.4, 7.1 Hz, 1H, 4-Ha), 1.17 (s, 3H, 3-CH3); 13C NMR (100 MHz, DMSO-d6): δ 190.76 (C-8),
178.79 (C-5), 161.11 (C-6), 158.31 (C-9), 144.01 (C-4a), 131.70 (C-9a), 127.95 (C-10a), 119.37
(C-10), 110.65 (C-8a), 109.33 (C-7), 70.51 (C-2), 69.41 (C-3), 56.78 (6-OMe), 41.67 (C-4), 29.75
(C-1), 25.07 (3-CH3); EIMS m/z 304 [M]+ (34), 286 (85), 271 (100), 257 (57), 243 (94), 229 (45), 215
(54), 201 (23).
Austrocortinin (4). Yellow solid (CH2Cl2); mp: 232–233 °C; 1H NMR (400 MHz, CDCl3): δ 13.59
(s, 1H, 8-OH), 13.47 (s, 1H, 5-OH), 8.25 (d, J = 8.0 Hz, 1H, 1-H), 8.16 (m, 1H, 4-H), 7.64
(d m, J = 8.0 Hz, 1H, 2-H), 6.72 (s, 1H, 7-H), 4.03 (s, 3H, 6-OMe), 2.57 (br s, 3H, 3-CH3); EIMS
m/z 284 [M]+ (100), 266 (28), 238 (23), 210 (22), 182 (8), 157 (5), 139 (6).
3.3. Synthetic Methods of Compounds
3.3.1. Synthesis of 2,3-O-(isopropylidene) Bostrycin (5)
To a solution of 1 (50 mg, 0.149 mmol) in 10 mL of tetrahydrofuran was added
2,2-dimethoxypropane (310 mg, 3.0 mmol) and p-toluenesulfonic acid (25.6 mg, 0.149 mmol). The
reaction mixture was stirred for 20 h at room temperature. The reaction mixture was diluted with water
(20 mL) and extracted with dichloromethane (3 × 50 mL). The combined organic phase was washed
with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated in vacuo.
The resulting residue was purified on a silica gel column using petroleum ether–dichloromethane
(v/v 1:1) as eluent to obtain 48.5 mg of compound 5. Yield 90%; red solid (CH2Cl2); mp: 228–229 °C;
1
IR (KBr): νmax = 3486, 3036, 2989, 2972, 2937, 2890, 1598, 1427, 1384 cm−1; H NMR (400 MHz,
CDCl3) δ 13.18 (s, 1H, 9-OH), 12.60 (s, 1H, 10-OH), 6.18 (s, 1H, 7-H), 5.51 (d, J = 2.7 Hz, 1H, 1-H),
4.41 (d, J = 2.7 Hz, 1H, 2-H), 3.93 (s, 3H, 6-OMe), 3.41 (d, J = 16.7 Hz, 1H, 4-Hb), 2.72 (d, J = 16.7 Hz,
1H, 4-Ha), 1.64 (s, 3H, 3-CH3), 1.40 (s, 3H, 2′-CH3), 1.03 (s, 3H, 3′-CH3); EIMS m/z 376 [M]+ (19),
361 (8), 318 (83), 301 (33), 289 (100), 273 (43), 257 (24), 243 (16).
3.3.2. Synthesis of 2,3-O-(3′-methylbut-2′-enyl) Bostrycin (6)
To a solution of 1 (50 mg, 0.149 mmol) in 10 mL of tetrahydrofuran was added 3-methyl-2-butenal
(37.5 mg, 0.45 mmol) and p-toluenesulfonic acid (25.6 mg, 0.149 mmol). The reaction mixture was
stirred for 10 h at room temperature. The reaction mixture was diluted with water (20 mL) and
extracted with dichloromethane (3 × 50 mL). The combined organic phase was washed with saturated
sodium chloride, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting
residue was purified on a silica gel column using dichloromethane as eluent to obtain 47.9 mg of
compound 6. Yield 80%; red solid (CH2Cl2); mp: 200–201 °C; IR (KBr): νmax = 3522, 3083, 2962,
1
2928, 2873, 1598, 1571, 1437, 1407, 1376 cm−1; H NMR (400 MHz, CDCl3) δ 13.09 (s, 1H, 9-OH),
12.53 (s, 1H, 10-OH), 6.12 (s, 1H, 7-H), 5.50 (d, J = 7.6 Hz, 1H, 1′-H), 5.45 (d, J = 2.5 Hz, 1H, 1-H),
4.72 (d septet, J = 7.6, 1.2 Hz, 1H, 2′-H), 4.20 (d, J = 2.5 Hz, 1H, 2-H), 3.92 (s, 3H, 6-OMe),
3.51 (d, J = 16.3 Hz, 1H, 4-Hb), 2.67 (d, J = 16.3 Hz, 1H, 4-Ha), 1.67 and 1.60 (d, J = 1.2 Hz, 4′-CH3
13
and 5′-CH3), 1.57 (s, 3H, 3-CH3); C NMR (100MHz, CDCl3): δ 186.45 (C-8), 180.60 (C-5), 160.69
(C-6), 158.54 (C-10), 156.95 (C-9), 141.85 (C-3′), 138.10 (C-9a), 137.86 (C-4a), 120.51 (C-2′), 110.97

Mar. Drugs 2012, 10
942
(C-10a), 109.92 (C-7), 108.79 (C-8a), 97.27 (C-1′), 83.05 (C-2), 79.12 (C-3), 62.82 (C-1),
56.77 (6-OMe), 31.27 (C-4), 26.34 (3-CH3), 25.73 and 18.39 (C-4′ and C-5′); EIMS m/z 402 [M]+ (5),
387 (2), 318 (100), 301 (42), 289 (96), 271 (39), 257 (26), 243 (19).
3.3.3. Synthesis of 1-O-(hydroxymethyl)-2,3-O-(methylene) Bostrycin (7)
To a solution of 1 (100 mg, 0.298 mmol) in 10 mL of tetrahydrofuran was added polyoxymethylene
(45 mg) and p-toluenesulfonic acid (51.2 mg, 0.298 mmol). The reaction mixture was stirred for 10 h
at room temperature. The reaction mixture was diluted with water (20 mL) and extracted with
dichloromethane (3 × 50 mL). The combined organic phase was washed with saturated sodium
chloride, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue
was purified on a silica gel column using dichloromethane–methanol (v/v 200:1) as eluent to obtain
27 mg of compound 7. Yield 24%; red solid (CH2Cl2); mp: 233–234 °C; IR (KBr): νmax = 3519, 3040,
2956, 2927, 2901, 2871, 1603, 1568, 1460, 1435, 1408 cm−1; 1H NMR (400 MHz, CDCl3): δ 13.23
(s, 1H, 9-OH), 12.64 (s, 1H, 10-OH), 6.17 (s, 1H, 7-H), 5.23 (d, J = 7.1 Hz, 1H, 1′-Hb), 5.19
(d, J = 4.4 Hz, 1H, 2′-Hb), 5.12 (dd, J = 7.5, 1.6 Hz, 1H, 2-H), 5.07 (d, J = 4.4 Hz, 1H, 2′-Ha), 5.04
(d, J = 7.1 Hz, 1H, 1′-Ha), 3.92 (s, 3H, 6-OMe), 3.63 (d, J = 7.5 Hz, 1H, 1-H), 3.18 (d, J = 18.9 Hz, 1H,
4-Hb), 2.69 (dd, J = 18.9, 1.6 Hz, 1H, 4-Ha), 1.50 (s, 3H, 3-CH3); 13C NMR (100 MHz, CDCl3):
δ 185.53 (C-8), 179.56 (C-5), 160.47 (C-6), 159.42 and 159.38 (C-9 and C-10), 136.41 (C-9a), 135.98
(C-4a), 110.53 (C-10a), 110.12 (C-7), 108.64 (C-8a), 93.69 and 91.57 (C-1′ and C-2′), 84.98 (C-2),
75.52 (C-3), 70.64 (C-1), 56.71 (6-OMe), 36.47 (C-4), 26.25 (3-CH3); EIMS m/z 378 [M]+ (86),
348 (14), 330 (45), 300 (100), 272 (80), 257 (45), 229 (28), 203 (11).
3.3.4. Synthesis of 2,3-O-(carbonyl) Bostrycin (8)
To a solution of 1 (100 mg, 0.298 mmol) and pyridine (235 mg, 0.298 mmol) in 5 mL of
dichloromethane at −10 °C was added a solution of triphosgene in 2 mL of dichloromethane dropwise.
The reaction mixture was stirred for 30 min, and then a saturated aqueous solution of ammonium
chloride (2 mL) was added. The reaction mixture was diluted with water (10 mL) and extracted with
dichloromethane (3 × 50 mL). The combined organic phase was successively washed with dilute
aqueous hydrochloric acid (2 M), water, saturated sodium chloride, dried over anhydrous magnesium
sulfate, and concentrated in vacuo. The resulting residue was purified on a silica gel column using
dichloromethane–methanol (v/v 200:1) as eluent to obtain 30.2 mg of compound 8. Yield 28%; red
solid (MeOH); mp: 246–247 °C; IR (KBr): νmax = 3403, 3081, 2977, 2942, 2850, 1814, 1603, 1570,
1
1435, 1411 cm−1; H NMR (400 MHz, DMSO-d6): δ 13.14 (s, 1H, 9-OH), 12.32 (s, 1H, 10-OH),
6.45 (s, 1H, 7-H), 6.20 (d, J = 4.1 Hz, 1H, 1-OH), 5.33 (dd, J = 4.1, 2.9 Hz, 1H, 1-H), 4.88
(d, J = 2.9 Hz, 1H, 2-H), 3.92 (s, 3H, 6-OMe), 3.54 (d, J = 16.5 Hz, 1H, 4-Hb), 2.81 (d, J = 16.5 Hz,
1H, 4-Ha), 1.76 (s, 3H, 3-CH3); 13C NMR (100 MHz, DMSO-d6): δ 188.35 (C-8), 182.04 (C-5), 161.05
(C-6), 154.53 (C-10), 153.90 (C-9), 152.64 (C=O), 135.93 (C-9a), 134.16 (C-4a), 111.60 (C-10a),
110.10 (C-7), 109.56 (C-8a), 82.59 (C-3), 81.25 (C-2), 59.75 (C-1), 57.11 (6-OMe), 29.89 (C-4), 27.21
(3-CH3); EIMS m/z 362 [M]+ (46), 318 (17), 300 (100), 282 (29), 254 (19), 229 (25), 216 (10),
201 (11).

Mar. Drugs 2012, 10
943
3.3.5. General Procedure: Synthesis of Compounds 9–22
To a solution of 1 (1 equiv, 50 mg, 0.149 mmol) in 10 mL of methanol was added the
corresponding amine (5 equiv). The reaction mixture was stirred at room temperature until the starting
material disappeared (with aniline and 4-methoxyaniline, the reaction mixture was heated to 50 °C).
The solvent was removed under reduced pressure. The resulting residue was purified on a silica gel
column using dichloromethane–methanol as eluent, and then a C18 reversed phase silica gel column
using methanol–water as eluent to obtain the corresponding products.
6-(Methylamino)-6-demethoxybostrycin (9). Yield 53.6%; red solid (MeOH); mp: 266–267 °C;
1
IR (KBr): νmax = 3532, 3457, 3389, 3319, 2973, 2928, 2843, 2808, 1584, 1517, 1418 cm−1; H NMR
(400 MHz, DMSO-d6): δ 14.47 (s, 1H, 9-OH), 12.32 (s, 1H, 10-OH), 8.02 (q, J = 5.0 Hz, 1H, NH),
5.57 (s, 1H, 7-H), 5.14 (d, J = 4.8 Hz, 1H, 1-OH), 4.96 (d, J = 4.6 Hz, 1H, 2-OH), 4.75 (t, J = 4.8 Hz,
1H, 1-H), 4.50 (s, 1H, 3-OH), 3.52 (t, J = 4.6 Hz, 1H, 2-H), 2.83 (d, J = 5.0 Hz, 3H, NHCH3), 2.72
(d, J = 17.8 Hz, 1H, 4-Hb), 2.64 (d, J = 17.8 Hz, 1H, 4-Ha), 1.23 (s, 3H, 3-CH3); 13C NMR (125 MHz,
DMSO-d6): δ 185.83 (C-8), 183.20 (C-5), 155.33 and 155.22 (C-9 and C-10), 150.44 (C-6), 139.49
(C-9a), 132.93 (C-4a), 109.60 (C-10a), 107.92 (C-8a), 98.58 (C-7), 76.38 (C-2), 69.36 (C-3), 68.56
(C-1), 34.75 (C-4), 29.08 (NHCH3), 25.68 (3-CH3); EIMS m/z 335 [M]+ (46), 317 (14), 288 (31),
261 (65), 246 (11), 233 (100), 218 (23), 204 (8).
6-(n-Propylamino)-6-demethoxybostrycin (10). Yield 50.2%; red solid (MeOH); mp: 210–211 °C;
IR (KBr): νmax = 3555, 3439, 3385, 3280, 3085, 2966, 2934, 2907, 2876, 1581, 1510, 1433 cm−1;
1H NMR (400 MHz, DMSO-d6): δ 14.51 (s, 1H, 9-OH), 12.33 (s, 1H, 10-OH), 7.97 (br t, 1H, NH),
5.67 (s, 1H, 7-H), 5.14 (d, J = 4.4 Hz, 1H, 1-OH), 4.95 (d, J = 4.2 Hz, 1H, 2-OH), 4.74 (t, J = 4.4 Hz,
1H, 1-H), 4.49 (s, 1H, 3-OH), 3.51 (t, J = 4.2 Hz, 1H, 2-H), 3.18 (q, J = 7.3 Hz, 2H, 1′-CH2), 2.72
(d, J = 17.8 Hz, 1H, 4-Hb), 2.64 (d, J = 17.8 Hz, 1H, 4-Ha), 1.60 (sextet, J = 7.4 Hz, 2H, 2′-CH2), 1.22
13
(s, 3H, 3-CH3), 0.91 (t, J = 7.5 Hz, 3H, 3′-CH3); C NMR (125 MHz, DMSO-d6): δ 185.87 (C-8),
183.30 (C-5), 155.27 and 155.25 (C-9 and C-10), 149.57 (C-6), 139.53 (C-9a), 132.89 (C-4a), 109.63
(C-10a), 107.83 (C-8a), 98.56 (C-7), 76.38 (C-2), 69.36 (C-3), 68.57 (C-1), 43.72 (C-1′), 34.74 (C-4),
25.67 (3-CH3), 20.67 (C-2′), 11.26 (C-3′); EIMS m/z 363 [M]+ (43), 345 (13), 316 (53), 302 (16),
289 (83), 261 (61), 232 (100), 218 (30).
6-(n-Butylamino)-6-demethoxybostrycin (11). Yield 48.5%; red solid (MeOH); mp: 236–237 °C;
1
IR (KBr): νmax = 3559, 3427, 3283, 3090, 2956, 2932, 2872, 1579, 1510, 1443 cm–1; H NMR
(500 MHz, DMSO-d6): δ 14.47 (s, 1H, 9-OH), 12.32 (s, 1H, 10-OH), 7.89 (t, J = 5.4 Hz, 1H, NH),
5.65 (s, 1H, 7-H), 5.07 (d, J = 4.7 Hz, 1H, 1-OH), 4.88 (d, J = 4.8 Hz, 1H, 2-OH), 4.75 (t, J = 4.7 Hz,
1H, 1-H), 4.43 (s, 1H, 3-OH), 3.52 (t, J = 4.8 Hz, 1H, 2-H), 3.21 (dt, J = 5.4, 7.5 Hz, 2H, 1′-CH2), 2.73
(d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.57 (pentet, J = 7.5 Hz, 2H, 2′-CH2), 1.34
(sextet, J = 7.3 Hz, 2H, 3′-CH2), 1.23 (s, 3H, 3-CH3), 0.91 (t, J = 7.5 Hz, 3H, 4′-CH3); 13C NMR
(125 MHz, DMSO-d6): δ 185.82 (C-8), 183.26 (C-5), 155.29 (C-9 and C-10), 149.53 (C-6), 139.52
(C-9a), 132.91 (C-4a), 109.62 (C-10a), 107.83 (C-8a), 98.50 (C-7), 76.38 (C-2), 69.36 (C-3), 68.58
(C-1), 41.80 (C-1′), 34.75 (C-4), 29.34 (C-2′), 25.67 (3-CH3), 19.60 (C-3′), 13.56 (C-4′); EIMS
m/z 377 [M]+ (43), 359 (18), 341 (21), 303 (98), 275 (70), 260 (24), 232 (100), 218 (35).

Mar. Drugs 2012, 10
944
6-(n-Hexylamino)-6-demethoxybostrycin (12). Yield 45%; red solid (MeOH); mp: 203–204 °C;
1
IR (KBr): νmax = 3557, 3384, 3285, 3089, 2955, 2929, 2859, 1578, 1512, 1436 cm−1; H NMR
(400 MHz, DMSO-d6): δ 14.47 (s, 1H, 9-OH), 12.33 (s, 1H, 10-OH), 7.91 (t, J = 6.1 Hz, 1H, NH),
5.65 (s, 1H, 7-H), 5.08 (d, J = 4.8 Hz, 1H, 1-OH), 4.89 (d, J = 4.6 Hz, 1H, 3-OH), 4.75 (t, J = 4.8 Hz,
1H, 1-H), 4.44 (s, 1H, 3-OH), 3.52 (t, J = 4.6 Hz, 1H, 2-H), 3.21 (dt, J = 6.1, 7.0 Hz, 2H, 1′-CH2), 2.73
(d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.58 (pentet, J = 7.0 Hz, 2H, 2′-CH2),
1.37–1.26 (m, 6H, 3′, 4′ and 5′-CH2), 1.23 (s, 3H, 3-CH3), 0.87 (t, J = 7.1 Hz, 3H, 6′-CH3); 13C NMR
(100 MHz, DMSO-d6): δ 185.90 (C-8), 183.36 (C-5), 155.31 and 155.27 (C-9 and C-10), 149.55 (C-6),
139.58 (C-9a), 132.92 (C-4a), 109.67 (C-10a), 107.87 (C-8a), 98.54 (C-7), 76.41 (C-2), 69.39 (C-3),
68.60 (C-1), 42.11 (C-1′), 34.77 (C-4), 30.87 (C-2′), 27.23 and 26.07 (C-3′ and C-4′), 25.70 (3-CH3),
21.97 (C-5′), 13.82 (C-6′); EIMS m/z 405 [M]+ (29), 387 (10), 358 (39), 331 (85), 303 (67), 382 (30),
323 (100), 218 (32).
6-(2′-Hydroxyethylamino)-6-demethoxybostrycin (13). Yield 30%; red solid (MeOH); mp:
1
202–203 °C; IR (KBr): νmax = 3374, 2968, 2924, 2898, 2857, 1587, 1518, 1439, 1402 cm–1; H NMR
(500 MHz, DMSO-d6): δ 14.45 (s, 1H, 9-OH), 12.31 (s, 1H, 10-OH), 7.70 (t, J = 6.0 Hz, 1H, NH),
5.73 (s, 1H, 7-H), 5.12 (d, J = 4.6 Hz, 1H, 1-OH), 4.92 (d, J = 4.4 Hz, 1H, 2-OH), 4.89 (t, J = 6.0 Hz,
1H, 2′-OH), 4.74 (t, J = 4.6 Hz, 1H, 1-H), 4.46 (s, 1H, 3-OH), 3.61 (q, J = 6.0 Hz, 2H, 2′-CH2), 3.51
(t, J = 4.4 Hz, 1H, 2-H), 3.29 (q, J = 6.0 Hz, 2H, 1′-CH2), 2.72 (d, J = 17.8 Hz, 1H, 4-Hb), 2.65
13
(d, J = 17.8 Hz, 1H, 4-Ha), 1.22 (s, 3H, 3-CH3); C NMR (125 MHz, DMSO-d6): δ 185.92 (C-8),
183.03 (C-5), 155.40 (C-9 and C-10), 149.79 (C-6), 139.56 (C-9a), 133.08 (C-4a), 109.55 (C-10a),
107.81 (C-8a), 98.95 (C-7), 76.38 (C-2), 69.36 (C-3), 68.58 (C-1), 58.41 (C-2′), 44.81 (C-1′), 34.78
(C-4), 25.68 (3-CH3); EIMS m/z 365 [M]+ (8), 349 (24), 327 (13), 314 (100), 298 (39), 282 (73),
276 (16), 232 (24).
6-[(2″-Hydroxyethoxy)ethylamino]-6-demethoxybostrycin (14). Yield 40.2%; red solid (MeOH);
1
mp: 112–113 °C; IR (KBr): νmax = 3376, 2973, 2922, 2872, 1584, 1516, 1439, 1373 cm−1; H NMR
(400 MHz, DMSO-d6): δ 14.38 (s, 1H, 9-OH), 12.30 (s, 1H, 10-OH), 7.68 (t, J = 5.6 Hz, 1H, NH),
5.74 (s, 1H, 7-H), 5.14 (d, J = 4.8 Hz, 1H, 1-OH), 4.94 (d, J = 4.6 Hz, 1H, 2-OH), 4.75 (t, J = 4.8 Hz,
1H, 1-H), 4.68 (t, J = 5.2 Hz, 1H, 2″-OH), 4.50 (s, 1H, 3-OH), 3.65 (t, J = 5.6 Hz, 2H, 1″-CH2),
3.58–3.50 (m, 5H, 2-H, 2′-CH2 and 2″-CH2), 3.40 (q, J = 5.6 Hz, 2H, 1′-CH2), 2.74 (d, J = 17.8 Hz, 1H,
4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.24 (s, 3H, 3-CH3); 13C NMR (100 MHz, DMSO-d6): δ 186.59
(C-8), 183.63 (C-5), 155.87 and 155.84 (C-9 and C-10), 150.12 (C-6), 140.09 (C-9a), 133.61 (C-4a),
110.09 (C-10a), 108.34 (C-8a), 99.65 (C-7), 76.92 (C-2), 72.60 (C-2′), 69.96 (C-3), 69.12 (C-1), 67.93
(C-1″), 60.65 (C-2″), 42.65 (C-1′), 35.29 (C-4), 26.16 (3-CH3); EIMS m/z 409 [M]+ (2), 389 (24),
373 (4), 357 (5), 327 (9), 314 (100), 300 (27), 282 (31).
6-(Phenylamino)-6-demethoxybostrycin (15). Yield 60.4%; red solid (MeOH); mp: 226–227 °C;
IR (KBr): νmax = 3576, 3560, 3409, 3248, 3037, 2968, 2919, 2901, 2850, 1587, 1572, 1521, 1444 cm−1;
1H NMR (500 MHz, DMSO-d6): δ 14.16 (s, 1H, 9-OH), 12.47 (s, 1H, 10-OH), 9.50 (br s, 1H, NH),
7.51–7.28 (m, 5H, Ar-H), 6.07 (s, 1H, 7-H), 5.13 (br s, 1H, 1-OH), 4.91 (d, J = 4.5 Hz, 1H, 2-OH),
4.81 (br t, 1H, 1-H), 4.45 (s, 1H, 3-OH), 3.57 (t, J = 4.6 Hz, 1H, 2-H), 2.80 (d, J = 17.9 Hz, 1H, 4-Hb),
2.72 (d, J = 17.9 Hz, 1H, 4-Ha), 1.28 (s, 3H, 3-CH3); 13C NMR (125 MHz, DMSO-d6): δ 186.46 (C-8),
182.83 (C-5), 155.87 and 155.73 (C-9 and C-10), 147.33 (C-6), 139.49 (C-9a), 137.65 (C-1′), 133.97

Mar. Drugs 2012, 10
945
(C-4a), 129.27 (C-3′ and C-5′), 125.63 (C-4′), 123.91 (C-2′ and C-6′), 109.63 (C-10a), 107.84 (C-8a),
101.33 (C-7), 76.40 (C-2), 69.36 (C-3), 68.51 (C-1), 34.86 (C-4), 25.68 (3-CH3); EIMS m/z 397 [M]+
(20), 377 (45), 361 (28), 345 (27), 324 (53), 295 (100), 280 (14), 266 (4).
6-(p-Methoxyphenylamino)-6-demethoxybostrycin (16). Yield 50.1%; red solid (MeOH); mp:
202–203 °C; IR (KBr): νmax = 3379, 3260, 3032, 2964, 2921, 2838, 1585, 1522, 1440, 1418 cm−1;
1H NMR (400 MHz, DMSO-d6): δ 14.22 (s, 1H, 9-OH), 12.43 (s, 1H, 10-OH), 9.43 (br s, 1H, NH),
7.33 (d, J = 8.6 Hz, 2H, Ar-H), 7.05 (br d, J = 8.6 Hz, 2H, Ar-H), 5.88 (s, 1H, 7-H), 5.11 (br s, 1H,
1-OH), 4.91 (br s, 1H, 2-OH), 4.79 (br t, 1H, 1-H), 4.46 (s, 1H, 3-OH), 3.81 (s, 3H, 4′-OMe), 3.56
(br t, 1H, 2-H), 2.79 (d, J = 17.9 Hz, 1H, 4-Hb), 2.70 (d, J = 17.9 Hz, 1H, 4-Ha), 1.27 (s, 3H, 3-CH3);
13C NMR (100 MHz, DMSO-d6): δ 186.55 (C-8), 183.34 (C-5), 157.25 (C-4′), 155.58 and 155.51 (C-9
and C-10), 148.02 (C-6), 139.60 (C-9a), 133.67 (C-4a), 130.22 (C-1′), 125.83 (C-2′ and C-6′), 114.58
(C-3′ and C-5′), 109.75 (C-10a), 107.95 (C-8a), 100.50 (C-7), 76.47 (C-2), 69.45 (C-3), 68.58 (C-1),
55.34 (4′-OMe), 34.89 (C-4), 25.76 (3-CH3); EIMS m/z 427 [M]+ (29), 407 (74), 392 (53), 360 (44),
325 (41), 310 (33), 284 (18), 263 (100).
6-(Benzylamino)-6-demethoxybostrycin (17). Yield 52.6%; red solid (MeOH); mp: 153–154 °C;
1
IR (KBr): νmax = 3384, 3064, 2971, 2927, 2907, 1581, 1513, 1438, 1373 cm−1; H NMR (400 MHz,
DMSO-d6): δ 14.30 (s, 1H, 9-OH), 12.36 (s, 1H, 10-OH), 8.51 (t, J = 6.4 Hz, 1H, NH), 7.36–7.25
(m, 5H, Ar-H), 5.58 (s, 1H, 7-H), 5.09 (d, J = 4.8 Hz, 1H, 1-OH), 4.90 (d, J = 4.6 Hz, 1H, 2-OH), 4.74
(t, J = 4.8 Hz, 1H, 1-H), 4.49 (d, J = 6.4 Hz, 2H, NHCH2Ph), 4.44 (s, 1H, 3-OH), 3.52 (t, J = 4.6 Hz,
1H, 2-H), 2.74 (d, J = 17.9 Hz, 1H, 4-Hb), 2.66 (d, J = 17.9 Hz, 1H, 4-Ha), 1.23 (s, 3H, 3-CH3);
13C NMR (100 MHz, DMSO-d6): δ 185.98 (C-8), 183.29 (C-5), 155.46 and 155.38 (C-9 and C-10),
149.54 (C-6), 139.57 (C-9a), 137.08 (C-1′), 133.24 (C-4a), 128.49 (C-3′ and C-5′), 127.16 and 127.12
(C-2′, C-4′ and C-6′), 109.67 (C-10a), 107.79 (C-8a), 99.84 (C-7), 76.41 (C-2), 69.38 (C-3), 68.56
(C-1), 45.25 (NHCH2), 34.79 (C-4), 25.70 (3-CH3); EIMS m/z 411 [M]+ (4), 391 (10), 359 (12),
337 (13), 302 (23), 284 (11), 218 (19), 204 (5), 91 (100).
6-(p-Methoxybenzylamino)-6-demethoxybostrycin (18). Yield 55.3%; red solid (MeOH); mp:
149–150 °C; IR (KBr): νmax = 3375, 3072, 2968, 2932, 2912, 2837, 1581, 1513, 1438, 1399 cm−1;
1H NMR (400 MHz, DMSO-d6): δ 14.33 (s, 1H, 9-OH), 12.35 (s, 1H, 10-OH), 8.47 (t, J = 6.4 Hz, 1H,
NH), 7.32–6.88 (m, 4H, Ar-H), 5.59 (s, 1H, 7-H), 5.10 (d, J = 4.8 Hz, 1H, 1-OH), 4.91 (d, J = 4.6 Hz,
1H, 2-OH), 4.74 (t, J = 4.8 Hz, 1H, 1-H), 4.45 (s, 1H, 3-OH), 4.41 (d, J = 6.4 Hz, 2H, NHCH2Ph), 3.73
(s, 3H, 4′-OMe), 3.51 (t, J = 4.6 Hz, 1H, 2-H), 2.73 (d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz,
1H, 4-Ha), 1.22 (s, 3H, 3-CH3); 13C NMR (100 MHz, DMSO-d6): δ 185.94 (C-8), 183.37 (C-5),
158.44 (C-4′), 155.45 and 155.35 (C-9 and C-10), 149.40 (C-6), 139.59 (C-9a), 133.20 (C-4a), 128.89
and 128.55 (C-1′, C-2′ and C-6′), 113.91 (C-3′ and C-5′), 109.66 (C-10a), 107.80 (C-8a), 99.74 (C-7),
76.42 (C-2), 69.40 (C-3), 68.58 (C-1), 55.02 (4′-OMe), 44.74 (NHCH2), 34.80 (C-4), 25.72 (3-CH3);
EIMS m/z 441 [M]+ (2), 425 (3), 407 (2), 389 (1), 320 (3), 302 (2), 274 (1), 232 (4), 121 (100).
6-(p-Fluorobenzylamino)-6-demethoxybostrycin (19). Yield 43.2%; red solid (MeOH); mp:
1
147–148 °C; IR (KBr): νmax = 3376, 3076, 2971, 2928, 2858, 1582, 1510, 1442, 1420 cm–1; H NMR
(400 MHz, DMSO-d6): δ 14.29 (s, 1H, 9-OH), 12.35 (s, 1H, 10-OH), 8.49 (t, J = 6.4 Hz, 1H, NH),
7.45–7.14 (m, 4H, Ar-H), 5.60 (s, 1H, 7-H), 5.09 (d, J = 4.7 Hz, 1H, 1-OH), 4.90 (d, J = 4.8 Hz, 1H,

Mar. Drugs 2012, 10
946
2-OH), 4.74 (t, J = 4.7 Hz, 1H, 1-H), 4.47 (d, J = 6.4 Hz, 2H, NHCH2Ph), 4.44 (s, 1H, 3-OH), 3.52
(t, J = 4.8 Hz, 1H, 2-H), 2.74 (d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.23 (s, 3H,
3-CH3); 13C NMR (100 MHz, DMSO-d6): δ 186.02 (C-8), 183.26 (C-5), 161.31 (C-4′), 155.46 and
155.36 (C-9 and C-10), 149.42 (C-6), 139.55 (C-9a), 133.26 (C-4a), 129.25 and 129.17 (C-1′, C-2′ and
C-6′), 115.21 (C-3′ and C-5′), 109.66 (C-10a), 107.78 (C-8a), 99.84 (C-7), 76.41 (C-2), 69.38 (C-3),
68.56 (C-1), 44.48 (NHCH2), 34.78 (C-4), 25.69 (3-CH3); ESIMS m/z 428 [M − 1]−.
6-(Piperidin-1-yl)-6-demethoxybostrycin (20). Yield 55%; red solid (MeOH); mp: 199–200 °C; IR
(KBr): νmax = 3557, 3399, 3054, 2928, 2855, 1597, 1576, 1548, 1447, 1429 cm−1; 1H NMR (400 MHz,
DMSO-d6): δ 14.10 (s, 1H, 9-OH), 12.58 (s, 1H, 10-OH), 6.03 (s, 1H, 7-H), 5.08 (d, J = 4.9 Hz, 1H,
1-OH), 4.88 (d, J = 4.7 Hz, 1H, 2-OH), 4.78 (t, J = 4.9 Hz, 1H, 1-H), 4.42 (s, 1H, 3-OH), 3.58 (br s,
4H, 2′-CH2 and 6′-CH2), 3.55 (t, J = 4.7 Hz, 1H, 2-H), 2.76 (d, J = 17.9 Hz, 1H, 4-Hb), 2.67 (d,
13
J = 17.9 Hz, 1H, 4-Ha), 1.68 (br s, 6H, 3′-CH2, 4′-CH2 and 5′-CH2), 1.25 (s, 3H, 3-CH3); C NMR
(100 MHz, DMSO-d6): δ 185.33 (C-8), 184.27 (C-5), 156.12 and 155.91 (C-9 and C-10), 153.93 (C-6),
138.50 (C-9a), 134.27 (C-4a), 111.14 (C-10a), 109.30 (C-7), 108.02 (C-8a), 76.45 (C-2), 69.45 (C-3),
68.50 (C-1), 50.40 (C-2′ and C-6′), 35.00 (C-4), 25.75 (3-CH3), 25.46 (C-3′ and C-5′), 23.67 (C-4′);
EIMS m/z 389 [M]+ (37), 371 (30), 353 (17), 316 (100), 300 (12), 286 (24), 258 (10), 242 (9).
6-(4′-Methylpiperidin-1-yl)-6-demethoxybostrycin (21). Yield 56.7%; red solid (MeOH); mp:
162–163 °C; IR (KBr): νmax = 3559, 3408, 3055, 2948, 2927, 2855, 1597, 1580, 1550, 1451,
1432 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 14.10 (s, 1H, 9-OH), 12.59 (s, 1H, 10-OH), 6.04 (s, 1H,
7-H), 5.09 (d, J = 4.8 Hz, 1H, 1-OH), 4.88 (d, J = 4.6 Hz, 1H, 2-OH), 4.78 (t, J = 4.8 Hz, 1H, 1-H),
4.42 (s, 1H, 3-OH), 4.13 (m, 2H, 2′-Hb and 6′-Hb), 3.55 (t, J = 4.6 Hz, 1H, 2-H), 3.05 (m, 2H, 2′-Ha
and 6′-Ha), 2.76 (d, J = 17.9 Hz, 1H, 4-Hb), 2.68 (d, J = 17.9 Hz, 1H, 4-Ha), 1.71 (m, 1H, 4′-H), 1.70
(m, 2H, 3′-Hb and 5′-Hb), 1.27 (m, 2H, 3′-Ha and 5′-Ha), 1.26 (s, 3H, 3-CH3), 0.97 (d, J = 6.1 Hz, 3H,
13
4′-CH3); C NMR (100 MHz, DMSO-d6): δ 185.13 (C-8), 184.04 (C-5), 156.33 and 156.05 (C-9 and
C-10), 153.83 (C-6), 138.48 (C-9a), 134.32 (C-4a), 111.11 (C-10a), 109.46 (C-7), 107.99 (C-8a),
76.43 (C-2), 69.42 (C-3), 68.50 (C-1), 49.63 and 49.56 (C-2′ and C-6′), 34.99 (C-4), 33.61 and 33.52
(C-3′ and C-5′), 29.99 (C-4′), 25.71 (3-CH3), 21.41 (4′-CH3); EIMS m/z 403 [M]+ (33), 385 (34),
367 (50), 330 (100), 314 (31), 300 (28), 286 (20), 270 (15).
6-(4′-Phenylpiperidin-1-yl)-6-demethoxybostrycin (22). Yield 45.6%; red solid (MeOH); mp:
221–222 °C; IR (KBr): νmax = 3538, 3397, 3033, 2956, 2933, 2900, 2870, 1570, 1539, 1495,
1
1455 cm−1; H NMR (400 MHz, DMSO-d6): δ 14.07 (s, 1H, 9-OH), 12.60 (s, 1H, 10-OH), 7.35–7.26
(m, 4H, Ar-H), 7.21 (m, 1H, Ar-H), 6.10 (s, 1H, 7-H), 5.12 (d, J = 4.7 Hz, 1H, 1-OH), 4.90
(d, J = 4.8 Hz, 1H, 2-OH), 4.77 (t, J = 4.7 Hz, 1H, 1-H), 4.44 (s, 1H, 3-OH), 4.27 (m, 2H, 2′-Hb and
6′-Hb), 3.53 (t, J = 4.8 Hz, 1H, 2-H), 3.15 (m, 2H, 2′-Ha and 6′-Ha), 2.83 (m, 1H, 4′-H), 2.75
(d, J = 17.9 Hz, 1H, 4-Hb), 2.66 (d, J = 17.9 Hz, 1H, 4-Ha), 1.91–1.76 (m, 4H, 3′-CH2 and 5′-CH2),
1.24 (s, 3H, 3-CH3); 13C NMR (100 MHz, DMSO-d6): δ 185.24 (C-8), 184.04 (C-5), 156.35 and
156.12 (C-9 and C-10), 153.80 (C-6), 145.33 (C-1″), 138.53 (C-9a), 134.39 (C-4a), 128.38, 126.67 and
126.19 (C-2″, C-3″, C-4″, C-5″ and C-6″), 111.12 (C-10a), 109.84 (C-7), 108.01 (C-8a), 76.43 (C-2),
69.42 (C-3), 68.49 (C-1), 50.00 and 49.92 (C-2′ and C-6′), 41.32 (C-4′), 34.99 (C-4), 32.77 and 32.66
(C-3′ and C-5′), 25.71 (3-CH3); EIMS m/z 465 [M]+ (53), 445 (85), 429 (91), 413 (66), 392 (100),
376 (12), 362 (16), 328 (62).

Mar. Drugs 2012, 10
947
3.3.6. General Procedure: Synthesis of Compounds 23–29
To a solution of 1 (1 equiv, 50 mg, 0.149 mmol) and triethylamine (8 equiv) in 10 mL of methanol
was added the corresponding thiol (4 equiv). The reaction mixture was stirred at 0–5 °C until the
starting material disappeared. The solvent was removed under reduced pressure. The resulting residue
was purified on a silica gel column using dichloromethane–methanol as eluent, and then a C18
reversed phase silica gel column using methanol–water as eluent to obtain the corresponding products.
6,7-bis(Ethylthio)-6-demethoxybostrycin (23). Yield 60.4%; red solid (MeOH); mp: 180–181 °C;
1
IR (KBr): νmax = 3561, 3379, 2968, 2923, 2865, 1604, 1572, 1486, 1447, 1426 cm−1; H NMR
(400 MHz, DMSO-d6): δ 13.22 (s, 1H, 9-OH), 13.04 (s, 1H, 10-OH), 5.29 (d, J = 4.5 Hz, 1H, 1-OH),
4.94 (d, J = 4.4 Hz, 1H, 2-OH), 4.75 (br t, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (t, J = 4.4 Hz, 1H, 2-H),
3.30–3.24 (m, 4H, 1′-CH2 and 1″-CH2), 2.74 (d, J = 18.5 Hz, 1H, 4-Hb), 2.67 (d, J = 18.5 Hz, 1H,
4-Ha), 1.24–1.20 (m, 9H, 3-CH3, 2′-CH3 and 2″-CH3); 13C NMR(100 MHz, DMSO-d6): δ 175.67
(C-5), 175.55 (C-8), 164.61 (C-9), 163.16 (C-10), 145.75 (C-7), 145.07 (C-6), 138.58 and 138.54
(C-4a and C-9a), 109.69 (C-10a), 109.32 (C-8a), 76.36 (C-2), 69.24 (C-3), 68.17 (C-1), 34.95 (C-4),
28.70 and 28.64 (C-1′ and C-1″), 25.53 (3-CH3), 15.03 and 15.00 (C-2′ and C-2″); EIMS m/z 426 [M]+
(8), 408 (10), 390 (3), 379 (21), 361 (100), 345 (28), 333 (79), 319 (22).
6,7-bis(n-Butylthio)-6-demethoxybostrycin (24). Yield 51.2%; red solid (MeOH); mp: 124–125 °C;
1
IR (KBr): νmax = 3551, 3400, 2958, 2929, 2871, 1599, 1532, 1431, 1377 cm−1; H NMR (400 MHz,
DMSO-d6): δ 13.23 (s, 1H, 9-OH), 13.05 (s, 1H, 10-OH), 5.29 (br s, 1H, 1-OH), 4.94 (br s, 1H, 2-OH),
4.75 (br s, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (d, J = 4.4 Hz, 1H, 2-H), 3.29–3.20 (m, 4H, 1′-CH2 and
1″-CH2), 2.73 (d, J = 18.4 Hz, 1H, 4-Hb), 2.67 (d, J = 18.4 Hz, 1H, 4-Ha), 1.58–1.46 (m, 4H, 2′-CH2
and 2″-CH2), 1.39 (sextet, J = 7.2 Hz, 4H, 3′-CH2 and 3″-CH2), 1.23 (s, 3H, 3-CH3), 0.86
13
(br t, J = 7.2 Hz, 6H, 4′-CH3 and 4″-CH3); C NMR (100 MHz, DMSO-d6): δ 175.85 (C-5), 175.74
(C-8), 164.55 (C-9), 163.07 (C-10), 146.16 (C-7), 145.52 (C-6), 138.59 and 138.55 (C-4a and C-9a),
109.76 (C-10a), 109.37 (C-8a), 76.39 (C-2), 69.30 (C-3), 68.20 (C-1), 35.00 (C-4), 34.15 and 34.09
(C-1′ and C-1″), 31.84 and 31.81 (C-2′ and C-2″), 25.61 (3-CH3), 21.10 (C-3′ and C-3″), 13.37 (C-4′
and C-4″); EIMS m/z 482 [M]+ (2), 464 (3), 446 (8), 430 (2), 405 (28), 389 (100), 373 (31), 361 (14).
6,7-bis(n-Hexylthio)-6-demethoxybostrycin (25). Yield 42.6%; red solid (MeOH); mp: 112–113°C;
1
IR (KBr): νmax = 3545, 3370, 2956, 2925, 2854, 1598, 1433, 1419, 1379 cm−1; H NMR (400 MHz,
DMSO-d6): δ 13.23 (s, 1H, 9-OH), 13.05 (s, 1H, 10-OH), 5.29 (d, J = 4.9 Hz, 1H, 1-OH), 4.94 (br s,
1H, 2-OH), 4.75 (br t, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (br d, 1H, 2-H), 3.29–3.19 (m, 4H, 1′-CH2
and 1″-CH2), 2.73 (d, J = 18.4 Hz, 1H, 4-Hb), 2.67 (d, J = 18.4 Hz, 1H, 4-Ha), 1.59–1.47 (m, 4H,
2′-CH2 and 2″-CH2), 1.44–1.30 (m, 4H, 3′-CH2 and 3″-CH2), 1.23 (br s, 11H, 3-CH3, 4′-CH2, 4″-CH2,
5′-CH2 and 5″-CH2), 0.87–0.79 (m, 6H, 6′-CH3 and 6″-CH3); 13C NMR (100 MHz, DMSO-d6):
δ 175.87 (C-5), 175.75 (C-8), 164.52 (C-9), 163.03 (C-10), 146.17 (C-7), 145.53 (C-6), 138.58 and
138.54 (C-4a and C-9a), 109.74 (C-10a), 109.36 (C-8a), 76.38 (C-2), 69.30 (C-3), 68.20 (C-1), 34.99
(C-4), 34.48 and 34.41 (C-1′ and C-1″), 30.65, 29.71, 29.68 and 27.58 (C-2′, C-2″, C-3′, C-3″, C-4′ and
C-4″), 25.60 (3-CH3), 21.91 (C-5′ and C-5″), 13.76 (C-6′ and C-6″); EIMS m/z 538 [M]+ (4), 502 (4),
433 (26), 417 (100), 401 (21), 389 (12), 347 (7), 335 (20).

Mar. Drugs 2012, 10
948
6,7-bis(2′-Hydroxyethylthio)-6-demethoxybostrycin (26). Yield 28.7%; red solid (MeOH); mp:
156–158 °C; IR (KBr): νmax = 3560, 3405, 2960, 2928, 2874, 2862, 1606, 1573, 1488, 1426 cm−1;
1H NMR (400 MHz, DMSO-d6): δ 13.17 (s, 1H, 9-OH), 12.99 (s, 1H, 10-OH), 5.27 (d, J = 4.3 Hz, 1H,
1-OH), 4.92 (br d, 1H, 2-OH), 4.89 and 4.88 (each br t, 1H, 2′-OH and 2″-OH), 4.77 (br t, 1H, 1-H),
4.47 (s, 1H, 3-OH), 3.61 (q, J = 4.8 Hz, 4H, 2′-CH2 and 2″-CH2), 3.55 (br t, 1H, 2-H), 3.41–3.32 (m,
4H, 1′-CH2 and 1″-CH2), 2.76 (d, J = 18.4 Hz, 1H, 4-Hb), 2.69 (d, J = 18.4 Hz, 1H, 4-Ha), 1.25 (s, 3H,
3-CH3); 13C NMR (100 MHz, DMSO-d6): δ 177.50 (C-5), 177.37 (C-8), 162.54 (C-9), 160.90 (C-10),
146.93 (C-7), 146.41 (C-6), 138.10 and 138.02 (C-4a and C-9a), 109.91 (C-10a), 109.49 (C-8a), 76.45
(C-2), 69.36 (C-3), 68.26 (C-1), 61.05 (C-2′ and C-2″), 37.13 and 37.09 (C-1′ and C-1″), 35.06 (C-4),
25.68 (3-CH3); ESIMS m/z 457 [M − 1]−.
6,7-bis(3′-Hydroxy-n-propylthio)-6-demethoxybostrycin (27). Yield 32.5%; red solid (MeOH); mp:
150–151 °C; IR (KBr): νmax = 3550, 3423, 2993, 2925, 2874, 2855, 1599, 1528, 1430, 1403, 1375 cm−1;
1H NMR (400 MHz, DMSO-d6): δ 13.20 (s, 1H, 9-OH), 13.03 (s, 1H, 10-OH), 5.25 (d, J = 4.3 Hz, 1H,
1-OH), 4.90 (d, J = 4.2 Hz, 1H, 2-OH), 4.75 (br t, 1H, 1-H), 4.50–4.43 (m, 3H, 3′-OH, 3″-OH and
3-OH), 3.52 (t, J = 4.2 Hz, 1H, 2-H), 3.47 (q, J = 6.4 Hz, 4H, 3′-CH2 and 3″-CH2), 3.36–3.28 (m, 4H,
1′-CH2 and 1″-CH2), 2.74 (d, J = 18.4 Hz, 1H, 4-Hb), 2.67 (d, J = 18.4 Hz, 1H, 4-Ha), 1.68 (pentet,
13
J = 6.4 Hz, 4H, 2′-CH2 and 2″-CH2), 1.23 (s, 3H, 3-CH3); C NMR (100 MHz, DMSO-d6): δ 176.23
(C-5), 176.12 (C-8), 164.14 (C-9), 162.61 (C-10), 146.32 (C-7), 145.73 (C-6), 138.51 and 138.48
(C-4a and C-9a), 109.85 (C-10a), 109.45 (C-8a), 76.43 (C-2), 69.35 (C-3), 68.23 (C-1), 59.09 (C-3′
and C-3″), 35.04 (C-4), 33.07 and 33.04 (C-1′ and C-1″), 31.46 and 31.40 (C-2′ and C-2″), 25.67
(3-CH3); ESIMS m/z 485 [M − 1]−.
6,7-(Ethan-1′,2′-yl-dithio)-6-demethoxybostrycin (28). Yield 24.8%; red solid (MeOH); mp: >300 °C;
1
IR (KBr): νmax = 3417, 2966, 2925, 2857, 1588, 1513, 1436, 1375 cm−1; H NMR (400 MHz,
DMSO-d6): δ 12.84 (s, 1H, 9-OH), 12.67 (s, 1H, 10-OH), 5.26 (br s, 1H, 1-OH), 4.94 (d, J = 4.4 Hz,
1H, 2-OH), 4.75 (d, J = 4.6 Hz, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (t, J = 4.4 Hz, 1H, 2-H), 3.35 (br s,
4H, 1′-CH2 and 2′-CH2), 2.75 (d, J = 18.2 Hz, 1H, 4-Hb), 2.68 (d, J = 18.2 Hz, 1H, 4-Ha), 1.23 (s, 3H,
13
3-CH3); C NMR (100 MHz, DMSO-d6): δ 180.54 and 180.42 (C-5 and C-8), 157.65 (C-9), 155.72
(C-10), 140.74 (C-7), 140.20 (C-6), 137.39 and 137.23 (C-4a and C-9a), 108.17 (C-10a), 107.66
(C-8a), 76.43 (C-2), 69.29 (C-3), 68.30 (C-1), 35.11 (C-4), 26.17 and 26.08 (C-1′ and C-2′), 25.67
(3-CH3); EIMS m/z 396 [M]+ (6), 376 (28), 360 (100), 344 (47), 332 (22), 307 (23), 294 (13), 279 (12).
6,7-(Butan-2′,3′-yl-dithio)-6-demethoxybostrycin (29). Yield 63.5%; red solid (MeOH); mp:
1
146–147 °C; IR (KBr): νmax = 3446, 3250, 2960, 2916, 2859, 1589, 1516, 1441, 1418 cm−1; H NMR
(400 MHz, DMSO-d6): δ 12.85 (s, 1H, 9-OH), 12.69 (s, 1H, 10-OH), 5.22 (br s, 1H, 1-OH), 4.91
(d, J = 4.6 Hz, 1H, 2-OH), 4.75 (d, J = 4.5 Hz, 1H, 1-H), 4.45 (s, 1H, 3-OH), 3.67 and 3.48 (each m,
1H, 2′-CH and 3′-CH), 3.54 (t, J = 4.6 Hz, 1H, 2-H), 2.75 (d, J = 18.3 Hz, 1H, 4-Hb), 2.68
(d, J = 18.3 Hz, 1H, 4-Ha), 1.32 and 1.30 (each d, J = 6.2 Hz, 3H, 1′-CH3 and 4′-CH3), 1.23 (s, 3H,
13
3-CH3); C NMR (100 MHz, DMSO-d6): δ 180.69 and 180.66 (C-5 and C-8), 157.58 (C-9), 155.64
(C-10), 139.83 (C-7), 138.71 (C-6), 137.39 and 137.18 (C-4a and C-9a), 108.38 (C-10a), 107.86
(C-8a), 76.46 (C-2), 69.33 (C-3), 68.32 (C-1), 35.11 (C-4), 25.70 (3-CH3), 22.99 and 22.89 (C-2′ and
C-3′), 17.60 (C-1′ and C-4′); EIMS m/z 424 [M]+ (8), 406 (5), 388 (3), 351 (29), 335 (5), 322 (9),
307 (5), 295 (13), 71 (100).

Mar. Drugs 2012, 10
949
3.4. Antitumor Activity in Vitro
3.4.1. Cell Culture
MCF-7, MDA-MB-435, A549, HepG2 and HCT-116 cells were cultured in Dulbecco’s
modification Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS, Hyclone, Logan, UT, USA), 2 mM L-glutamine, 100 μg/mL streptomycin and
100 U/mL penicillin (Invitrogen). MCF-10A cells were cultured in keratinocyte serum free medium
(KSFM) supplemented with 0.1–0.2 ng/mL human recombinant epidermal growth factor and
20–30 μg/mL bovine pituitary extract (Invitrogen). The cells were incubated at 37 °C in a humidified
atmosphere with 5% CO2.
3.4.2. Assessment of Antitumor Activity by MTT Assay
Cells were harvested during logarithmic growth phase and seeded in 96-well plates at a density of
1 × 104 cells/mL, and cultured at 37 °C in a humidified incubator (5% CO2) for 24 h, followed by
exposure to various concentrations of compounds tested for 48 h. Subsequently 20 μL of MTT
(Genview, Houston, TX, USA) solution (5 mg/mL) was added to each well and mixed, the cells were
then incubated for an additional 4 h. Culture supernatant was moved, 150 μL of DMSO (Sangon
Biotech, Shanghai, China) was added to each well to fully dissolve the MTT-formazan crystals. Cell
growth inhibition was determined by measuring the absorbance (Abs) at λ = 570 nm using a
microplate reader and calculated according to the following equation:
Growth inhibition = (1 − OD of treated cells/OD of control cells) × 100%
The half maximal inhibitory concentrations (IC50) were obtained from liner regression analysis of
the concentration-response curves plotted for each tested compound.
4. Conclusions
This paper has reported the synthesis and biological evaluation of a novel class of bostrycin
derivatives against a panel of tumor cells along with one type of immortalized human breast epithelial
cells. Encouragingly, some modified compounds displayed superior cytotoxicity over the parent
compound bostrycin and equal anticancer potency to epirubicin which served as a reference anticancer
drug. However, the majority of compounds also exhibited marked cytotoxicity towards MCF-10A cells.
Preliminary SAR study indicated that the enhanced cytotoxicity was fulfilled by dioxylcarbonyl groups
at C-2 and C-3 positions, tertiary amino groups at C-6 position and alkylthio groups at C-6 and C-7
positions of the bostrycin. These positive results could serve as a valuable guideline for further
research on the structural optimization, mechanism study and development of bostrycin derivatives as
novel antitumor agents.

Mar. Drugs 2012, 10
950
Acknowledgments
This research was supported by grants from the National Natural Science Foundation of China
(No. 20972197, No. 41176128), the 863 Foundation of China (No. 2011AA09070201), the Key
Science and Technique Research Project of Guangdong Province of China (No. 2010B030600003,
No. 2010B030600004, No. 2011A080403006), National Science and Technique Major Project
(No. 2012ZX09102-101-017), University-industry Cooperation Projects of Guangdong Province and
Ministry of Education (No. 2008B090500171) and Guangzhou Project of Science & Technology
Planning (No. 2010J1-E331).
References
1. Gill, M.; Strauch, R.J. New tetrahydroanthraquinones from the genus Cortinarius. Tetrahedron
Lett. 1985, 26, 2593–2596.
2. Gill, M.; Smrdel, A.F. Deoxyaustrocortilutein and deoxyaustrocortirubin, tetrahydroanthraquinones
from the genus Cortinarius. Phytochemistry 1987, 26, 2999–3001.
3. Gill, M.; Smrdel, A.F.; Strauch, R.J.; Begley, M.J. Pigments of fungi. Part 12. Structure and
absolute stereochemistry of antibiotic tetrahydroanthraquinones from the fungus Dermocybe
splendida Horak. X-ray structure determination of austrocortirubin phenylboronate and
austrocortilutein acetonide. J. Chem. Soc. Perkin Trans. 1 1990, 1583–1592.
4. Elsworth, C.; Gill, M.; Ten, A. Pigments of Fungi. LXII* (1S,3R)-Austrocortirubin: Isolation
from the fungus Dermocybe splendida and synthesis from (S)-Citramalic acid. Aust. J. Chem.
1999, 52, 1115–1117.
5. Alvi, K.A.; Rabenstein, J. Auxarthrol A and Auxarthrol B: Two new tetrahydroanthraquinones
from Auxarthron umbrinum. J. Ind. Microbiol. Biotechnol. 2004, 31, 11–15.
6. Yagi, A.; Okamura, N.; Haraguchi, H.; Abo, T.; Hashimoto, K. Antimicrobial
tetrahydroanthraquinones from a strain of Alternaria solani. Phytochemistry 1993, 33, 87–91.
7. Feng, S.X.; Hao, J.; Chen, T.; Samuel, X. A new anthraquinone and two new
tetrahydroanthraquinones from the roots of Prismatomeris connata. Helv. Chim. Acta 2011, 94,
1843–1849.
8. Kettner, M.; Nemec, P.; Kovác, S.; Balanová, J. Dactylarin, a new antiprotozoal antibiotic from
Dactylaria lutea. J. Antibiot. 1973, 26, 692–696.
9. Charudattan, R.; Rao, K.V. Bostrycin and 4-deoxybostrycin: Two nonspecific phytotoxins
produced by Alternaria eichhorniae. Appl. Environ. Microbiol. 1982, 43, 846–849.
10. Sturdík, E.; Drobnica, L. Interaction of cytotoxic antibiotic dactylarin with glycolytic thiol
enzymes in Ehrlich ascites carcinoma cells. J. Antibiot. 1981, 34, 708–712.
11. Haraguchi, H.; Abo, T.; Fukuda, A.; Okamura, N.; Yagi, A. Mode of phytotoxic action of
Altersolanols. Phytochemistry 1996, 43, 989–992.
12. Jiang, G.C.; Lin, Y.C.; Zhou, S.N.; Vrumoed, L.L.P.; Jones, E.B.G. Studies on the secondary
metabolites of mangrove fungus No. 1403 from the South China Sea. Acta. Sci. Nat. Univ.
Sunyatseni 2000, 39, 68–72.

Mar. Drugs 2012, 10
951
13. She, Z.G.; Chen, S.P.; Lin, Y.C.; Yuan, J.; Pang, J.Y.; Li, M.F.; Liu, L.; Wu, Y.H.; Cai, X.L.;
Zheng, M.Y.; et al. Process for preparation of quinone-like compound bostrycin, and its
application for treating neoplasm. China Patent Application CN 101544556 A, 30 September 2009.
14. Xia, X.K.; Li, Q.; Li, J.; Shao, C.L.; Zhang, J.Y.; Zhang, Y.G.; Liu, X.; Lin, Y.C.; Liu, C.H.;
She, Z.G. Two new derivatives of griseofulvin from the mangrove endophytic fungus
Nigrospora sp. (Strain No. 1403) from Kandelia candel (L.) Druce. Planta Med. 2011, 77,
1735–1738.
15. Nota, T.; Take, T.; Watanabe, T.; Abe, J. The structure of bostrycin. Tetrahedron 1970,
26, 1339–1346.
16. Nota, T.; Take, T.; Otani, M.; Miyauchi, K.; Watanabe, T.; Abe, J. Structure of bostrycin.
Tetrahedron Lett. 1968, 58, 6087–6090.
17. Takenada, A.; Furusaki, A.; Watanabe, T.; Nota, T.; Take, T.; Watanabe, T.; Abe, J. The crystal
and molecular structure of bostrycin p-bromobenzoate, a derivative of bostrycin. Tetrahedron
Lett. 1968, 58, 6091–6094.
18. Kelly, T.R.; Saha, J.K. Bostrycin: Structure correction and synthesis. J. Org. Chem. 1985, 50,
3679–3685.
19. Larsen, D.S.; Stoodley, R.J. An enantioselective synthesis of (+)-bostrycin leading to a revision of
the absolute configuration of its natural antipode. Tetrahedron 1990, 46, 4711–4732.
20. Xie, G.E.; Zhu, X.; Li, Q.; Gu, M.H.; He, Z.j.; Wu, J.H.; Li, J.; Lin, Y.C.; Li, M.F.; She, Z.G.;
Yuan, J. SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer
activity by suppression of the Akt/FOXO pathway. Br. J. Pharmacol. 2010, 159, 689–697.
21. Xia, X.K.; Huang, H.R.; She, Z.G.; Shao, C.L.; Liu, F.; Cai, X.L.; Vrijmoed, L.L.P.; Lin, Y.C.
1H and 13C NMR assignments for five anthraquinones from the mangrove endophytic fungus
Halorosellinia sp. (No. 1403). Magn. Reson. Chem. 2007, 45, 1006–1009.
22. Xu, C.L.; Wang, J.F.; Gao, Y.; Lin, H.Y.; Du, L.; Yang, S.S.; Long, S.M.; She, Z.G.; Cai, X.L.;
Zhou, S.N.; Lu, Y.J. The anthracenedinone compound bostrycin induces mitochondria-mediated
apoptosis in the yeast Saccharomyces cerevisiae. FEMS Yeast Res. 2010, 10, 297–308.
23. Chen, W.S.; Hou, J.N.; Guo, Y.B.; Yang, H.L.; Xia, C.M.; Lin, Y.C.; She, Z.G. Bostrycin inhibits
proliferation of human lung carcinoma A549 cells via downregulation of the P13K/Akt pathway.
J. Exp. Clin. Cancer Res. 2011, 30, 1–7.
24. Tandon, V.K.; Maurya, H.K. “On water”: Unprecedented nucleophilic substitution and addition
reactions with 1,4-quinones in aqueous suspension. Tetrahedron Lett. 2009, 50, 5896–5902.
25. Tandon, V.K.; Maurya, H.K.; Tripathi, A.; Shivakesva, G.B.; Shukla, P.K.; Srivastava, A.;
Panda, D. 2,3-Disubstituted-1,4-naphthoquinones, 12H-benzo[b]phenothiazine-6,11-diones and
related compounds: synthesis and biological evaluation as potential antiproliferative and
antifungal agents. Eur. J. Med. Chem. 2009, 44, 1086–1092.
26. Tandon, V.K.; Yadav, D.B.; Maurya, H.K.; Chaturvedi, A.K.; Shukla, P.K. Design, synthesis, and
biological evaluation of 1,2,3-trisubstituted-1,4-dihydrobenzo[g]quinoxaline-5,10-diones and
related compounds as antifungal and antibacterial agents. Bioorg. Med. Chem. 2006, 14,
6120–6126.

Mar. Drugs 2012, 10
952
27. Tandon, V.K.; Maurya, H.K.; Mishra, N.N.; Shukla, P.K. Design, synthesis and biological
evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent
antifungal and antibacterial agents. Eur. J. Med. Chem. 2009, 44, 3130–3137.
28. Huang, C.H.; Pan, J.H.; Chen, B.; Yu, M.; Huang, H.B.; Zhu, X.; Lu, Y.J.; She, Z.G.; Lin, Y.C.
Three bianthraquinone derivatives from the mangrove endophytic fungus Alternaria sp. ZJ9-6B
from the South China Sea. Mar. Drugs 2011, 9, 832–843.
29. Bonfante, V.; Bonadonna, G.; Villani, F.; di Fronzo, G.; Martini, A.; Casazza, A.M. Preliminary
phase I study of 4′-epi-adriamycin. Cancer Treat. Rep. 1979, 63, 915–918.
30. Schauer, P.K.; Wittes, R.E.; Gralla, R.J.; Casper, E.S.; Young, C.W. A phase I trial of
4′-epi-adriamycin. Cancer Clin. Trials 1981, 4, 433–437.
31. Bonfante, V.; Villani, F.; Bonadonna, G. Toxic and therapeutic activity of 4′-epi-doxorubicin.
Tumori 1982, 68, 105–111.
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).